Automate Your Wheel Strategy on ABBV
With Tiblio's Option Bot, you can configure your own wheel strategy including ABBV - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ABBV
- Rev/Share 32.4474
- Book/Share 0.8269
- PB 237.3353
- Debt/Equity 49.2176
- CurrentRatio 0.7602
- ROIC 0.1793
- MktCap 336711168000.0
- FreeCF/Share 8.7019
- PFCF 21.8857
- PE 80.3376
- Debt/Assets 0.5133
- DivYield 0.0335
- ROE 0.9559
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | ABBV | Citigroup | Buy | Neutral | -- | $205 | May 14, 2025 |
| Initiation | ABBV | Cantor Fitzgerald | -- | Overweight | -- | $210 | April 22, 2025 |
| Resumed | ABBV | BofA Securities | -- | Neutral | -- | $191 | Dec. 10, 2024 |
| Downgrade | ABBV | Daiwa Securities | Outperform | Neutral | -- | $180 | Dec. 5, 2024 |
| Initiation | ABBV | Bernstein | -- | Market Perform | -- | $203 | Oct. 17, 2024 |
News
Final Trades: Abbvie, Boeing, Oracle and Joby Aviation
Published: July 10, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee give you their top stocks to watch for the second half.
Read More
Trump threatens impose up to 200% tariff on pharmaceuticals 'very soon'
Published: July 08, 2025 by: CNBC
Sentiment: Neutral
President Donald Trump threatened to impose up to 200% tariffs on pharmaceuticals imported into the U.S. "very soon." But he suggested that those levies would not go into effect immediately, saying he will "give people about a year, year and a half.
Read More
How Will Skyrizi and Rinvoq Sales Aid AbbVie's Upcoming Q2 Results?
Published: July 08, 2025 by: Zacks Investment Research
Sentiment: Neutral
ABBV leans on Skyrizi and Rinvoq sales strength to offset Humira's decline ahead of its Q2 earnings report.
Read More
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
Published: July 07, 2025 by: Zacks Investment Research
Sentiment: Positive
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Is It Worth Investing in AbbVie (ABBV) Based on Wall Street's Bullish Views?
Published: July 03, 2025 by: Zacks Investment Research
Sentiment: Positive
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Read More
AbbVie Stock At $190: Premium Pricing For A Transformation Story
Published: July 02, 2025 by: Forbes
Sentiment: Positive
AbbVie (NASDAQ:ABBV) has distinguished itself as one of the top performers in the healthcare sector this year, with its stock rising by 6% while the broader S&P 500 healthcare index fell by 1%. This outperformance is indicative of investor confidence in the pharmaceutical giant's ambitious transformation strategy as it navigates the post-Humira period.
Read More
Why AbbVie (ABBV) is a Top Value Stock for the Long-Term
Published: July 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Will AbbVie's Acquisition Spree Aid Pipeline Growth?
Published: July 02, 2025 by: Zacks Investment Research
Sentiment: Neutral
ABBV's $2.1 billion Capstan deal and 20+ recent acquisitions sharpen its pipeline edge across immunology and beyond.
Read More
ABBV to Boost Immunology Pipeline With Capstan Buyout for $2.1B
Published: July 01, 2025 by: Zacks Investment Research
Sentiment: Positive
AbbVie's $2.1 billion Capstan deal brings a novel in-vivo CAR-T therapy and tLNP platform to boost its immunology pipeline.
Read More
Abbvie confirms $2.1bn Capstan swoop
Published: June 30, 2025 by: Proactive Investors
Sentiment: Positive
Abbvie Inc (NYSE:ABBV) has agreed to acquire Capstan Therapeutics in a deal worth up to $2.1 billion, expanding its pipeline with a potential first-in-class treatment for autoimmune diseases and gaining access to a new type of RNA delivery system. The acquisition will give the pharma giant control of CPTX2309, a lipid nanoparticle-based therapy that delivers mRNA directly into the body to program the immune system.
Read More
AbbVie Adds More Than $24B in 6 Months: How to Play ABBV Stock
Published: June 27, 2025 by: Zacks Investment Research
Sentiment: Positive
ABBV adds $24B in market cap as Skyrizi and Rinvoq drive growth post-Humira, with more upside from a strong pipeline.
Read More
Jim Cramer's Safest Stock For Retirees
Published: June 26, 2025 by: 24/7 Wall Street
Sentiment: Positive
Jim Cramer has a mixed record when it comes to choosing stocks.
Read More
Here's Why AbbVie (ABBV) is a Strong Momentum Stock
Published: June 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Read More
Will AbbVie's Growing Oncology Portfolio Aid Top-line Growth?
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Positive
ABBV's growing oncology portfolio, now spanning five therapies, is helping offset Imbruvica's sales decline and boost top-line growth.
Read More
AbbVie's Venclexta Misses Goal in Myelodysplastic Syndromes Study
Published: June 17, 2025 by: Zacks Investment Research
Sentiment: Negative
Venclexta fails to meet survival goals in ABBV's phase III MDS study, marking another clinical setback for the cancer drug.
Read More
Is AbbVie (ABBV) a Buy as Wall Street Analysts Look Optimistic?
Published: June 17, 2025 by: Zacks Investment Research
Sentiment: Neutral
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Read More
Here's Why AbbVie (ABBV) is a Strong Value Stock
Published: June 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
5 Large Drug Stocks That Are Poised to Ride on Sector Recovery
Published: June 16, 2025 by: Zacks Investment Research
Sentiment: Neutral
In the Large-Cap Pharmaceuticals industry, AbbVie, Novartis, Pfizer, Sanofi and Bayer are worth retaining amid macro pressure and rising innovation.
Read More
AbbVie says blood cancer drug fails late-stage trial
Published: June 16, 2025 by: Reuters
Sentiment: Negative
AbbVie said on Monday its treatment for a group of blood cancers failed to meet the main goal of overall survival in a late-stage trial.
Read More
AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes
Published: June 16, 2025 by: PRNewsWire
Sentiment: Neutral
NORTH CHICAGO, Ill. , June 16, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced the global Phase 3 VERONA trial evaluating venetoclax in combination with azacitidine in the treatment of newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) did not meet the primary endpoint of overall survival (OS) with a hazard ratio (HR) of 0.908; stratified log-rank, p=0.3772.
Read More
Giant-Cell Arteritis Market Heats up with AbbVie's RINVOQ Approval | DelveInsight
Published: June 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
The FDA has approved AbbVie's RINVOQ (upadacitinib) for the treatment of giant cell arteritis, making it the ninth approved indication for the drug. This also marks the first time an oral JAK inhibitor has been approved for this prevalent form of vasculitis in Western countries. RINVOQ's approval has sparked competition among other pharmaceutical companies in the giant cell arteritis market. The FDA has approved AbbVie's RINVOQ (upadacitinib) for the treatment of giant cell arteritis, making it the ninth approved indication for the drug. This also marks the first time an oral JAK inhibitor has been approved for this prevalent form …
Read More
U.S. FDA Approves Expanded Indication for AbbVie's MAVYRET® (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus
Published: June 11, 2025 by: PRNewsWire
Sentiment: Neutral
MAVYRET® (glecaprevir/pibrentasvir) is the first and only oral eight-week pangenotypic treatment option approved for people with acute or chronic hepatitis C virus (HCV)* With this approval, providers can now treat HCV patients immediately at the time of diagnosis HCV is a curable condition, but patients can often go undiagnosed.1 If left untreated, people with acute HCV could progress to chronic disease, including liver-related complications, such as cirrhosis or liver cancer1 The approval supports global clinical guidelines to advance testing and treatment for people with HCV regardless of chronicity, and supports public health goals for disease elimination NORTH CHICAGO, Ill. , …
Read More
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
Published: June 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Read More
Have Skyrizi and Rinvoq Successfully Saved AbbVie From Humira LoE?
Published: June 10, 2025 by: Zacks Investment Research
Sentiment: Positive
ABBV eyes $24.7 billion from Skyrizi and Rinvoq in 2025 as ex-Humira growth offsets sharp sales drop post-U.S. patent loss.
Read More
Can New Cancer Drug Emrelis Drive AbbVie's Oncology Franchise?
Published: June 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Emrelis wins FDA approval, marking ABBV's first lung cancer drug and strengthening its oncology reach into solid tumors.
Read More
Contact The Gross Law Firm by June 3, 2025 Deadline to Join Class Action Against Cerevel Therapeutics Holdings, Inc. (ABBV)
Published: June 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV).
Read More
Profit From the Silver Tsunami: Must-Watch Senior Care & Aging Stocks
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Positive
BSX, ABBV, AMGN and DXCM are tapping into the aging boom with cutting-edge tech, chronic care drugs and senior-focused innovations.
Read More
Bert's May 2025 Dividend Income Summary
Published: June 03, 2025 by: Seeking Alpha
Sentiment: Negative
Our dividend income dropped by 15% in May. We had Healthpeak Properties change the structure of its dividend. June will be a very exciting month and I cannot wait to see the dividend distributions for our ETFs, especially SCHD.
Read More
AbbVie Invites People Living with Migraine to Enter the Second Annual AbbVie Migraine Career Catalyst Award™ Contest to Support Their Professional Goals
Published: June 03, 2025 by: PRNewsWire
Sentiment: Neutral
The AbbVie Migraine Career Catalyst Award™ contest is now open for entries, offering financial support to help winners pursue career and professional development goals. As the only company with three approved products designed to meet patient needs across the spectrum of migraine, AbbVie is committed to supporting the migraine community beyond treatment.
Read More
About AbbVie Inc. (ABBV)
- IPO Date 2013-01-02
- Website https://www.abbvie.com
- Industry Drug Manufacturers - General
- CEO Robert A. Michael CPA
- Employees 55000